SUNNYVALE, Calif. and NEW YORK, June 27, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS), announced today that Montefiore doctors have treated the first cancer patients in New York with the advanced Radixact™ Treatment Delivery System. The system was designed to deliver image-guided intensity-modulated (IG-IMRT) radiation therapy, an extremely precise form of radiation therapy. Montefiore is the only hospital in New York State, and in the greater New York area, to have this equipment.
The Radixact System is the next generation TomoTherapy® platform developed to enable doctors to more efficiently and effectively deliver precise radiation treatments to more patients with cancer every day. What makes the Radixact technology different from conventional radiation systems is the integration of a CT scanner with the radiation therapy delivery system. The built-in CT scanner performs daily imaging before each treatment session to determine the shape and position of the tumor. This allows for accurate and precise tumor targeting, while reducing the radiation dose to normal, healthy tissue. Only then, is radiation delivered from 360 degrees around the patient's body allowing for treatment of any target, irrespective of its length.
Daily pretreatment imaging, coupled with the System's Accuray Precision™ Treatment Planning System and PreciseART™ Adaptive Radiation Therapy software, informs precise treatment planning and mid-course decision-making, so clinical teams can instantly adapt therapy to:
Identifying and correcting for any variations in patient positioning, as well as biological changes, ensures the continued precision and safe delivery of the radiation dose to the target area, resulting in fewer long term side effects.
The Radixact System is capable of treating all standard radiation therapy indications including breast, head and neck, lung, and prostate cancers, in addition to complex treatments such as total marrow irradiation. The Montefiore patients were treated for prostate cancer and plans are also in place to use the System for patients with Ob/Gyn related cancers and head and neck cancers, as these often require alterations to therapy mid-course due to changes in tumor size, location and individual weight.
See a video of the System and its unique benefits here:
"We could not be more thrilled to have this amazing technology here at Montefiore, along with the clinical expertise to guide its use," said Shalom Kalnicki, M.D., F.A.C.R.O., professor and chair, Department of Radiation Oncology, Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine. "We know the ability to adapt the radiation dose to the actual target and normal tissue position and shape is key to the future of radiation therapy. This technology is so sophisticated it can streamline treatment so cures are more frequent and patients are better protected from side effects they have suffered in the past. The Radixact System is an exciting step forward solidifying the Montefiore Einstein Center for Cancer Care's place on the frontier of cancer treatment."
According to the Centers for Disease Control and Prevention (CDC), the state of New York has the third highest cancer rate in the United States.1 More than 105,000 people in New York are diagnosed with cancer each year, or approximately 287 people each day.2 Innovations such as the Radixact System are helping to make it possible for people who are diagnosed with cancer to live longer with a better quality of life than was previously possible.
"Montefiore is a leading Academic Medical Center known around the world for its innovate cancer research and care," said Josh Levine, President and Chief Executive Officer of Accuray. "We are proud that they selected the innovative Radixact System to enhance the range of treatment options they provide to their patients. The Montefiore team's early experience with the system has been exceedingly positive, similar to what we are hearing from other physicians, and reinforces the value it can bring to a radiation oncology department by improving the effectiveness and efficiency with which radiation treatments can be delivered."
Important Safety Information
For Important Safety Information please refer to http://www.accuray.com/safety-statement
About Montefiore Health System
Montefiore Health System is one of New York's premier academic health systems and is a recognized leader in providing exceptional quality and personalized, accountable care to approximately three million people in communities across the Bronx, Westchester and the Hudson Valley. It is comprised of 11 hospitals, including the Children's Hospital at Montefiore, Burke Rehabilitation Hospital and close to 200 outpatient care sites. The advanced clinical and translational research at its medical school, Albert Einstein College of Medicine, directly informs patient care and improves outcomes. From the Montefiore-Einstein Centers of Excellence in cancer, cardiology and vascular care, pediatrics, and transplantation, to its preeminent school-based health program, Montefiore is a fully integrated healthcare delivery system providing coordinated, comprehensive care to patients and their families. For more information please visit www.montefiore.org. Follow us on Twitter and view us on Facebook and YouTube
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to advantages of new technology, clinical applications, clinical results, successful adoption of new technologies, patient experiences and outcomes, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's reports on Form 10-Q, filed on November 1, 2016, February 3, 2017, and May 5, 2017, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Accuray Media Contacts
+1 (408) 789-4426
+1 (781) 684-0770
Accuray Investor Contact
Investor Relations, EVC Group
+1 (415) 652-9100
Montefiore Health System Media Contact
1https://www.cdc.gov/cancer/dcpc/data/state.htm accessed on April 25, 2017
2https://statecancerprofiles.cancer.gov/incidencerates/index.php?stateFIPS=36&cancer=001&race=00&sex=0&age=001&type=incd&sortVariableName=rate&sortOrder=default#results accessed on April 26, 2017
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/montefiore-is-first-in-ny-metropolitan-area-to-treat-cancer-patients-with-accuray-radixact-system-300479908.html
SOURCE Accuray Incorporated